Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

BioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting ...

24 August 2026 · By · Wire by Fusion42

Published

24 August 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at markets.businessinsider.com →

◆ Verified

Fusion42 · 25 August 2026 · Fusion42 review

BioCardia announced that the FDA has confirmed the meeting minutes for their Helix Transendocardial Delivery Catheter, supporting a follow-on De Novo pre-submission for regulatory approval in the United States.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

Medtech founders developing cardiac devices must prepare for accelerated FDA engagement as pre-submission feedback signals smoother pathways to market for innovative delivery catheters. You need to sharpen your regulatory strategy now to turn FDA interactions into faster approvals.

◆ Coverage

1 source · 24 Aug 2026

◆ Related on Wire

◆ Topics

Medtechfdamedical-deviceregulatory-approvalmedtechcardiology